Press release
Unique CAR-T serial killing dynamics revealed using VivaCyte novel assay
4 November 2025
Homepage
Accelerate Cell Therapy R&D with Automated, Single-Cell Function & Potency Assays
What we do
At the core of our mission is the CC-Array®, an innovative patented microfluidic plate that enables the simultaneous analysis of thousands of miniaturized co-cultures. This technology allows us to move beyond bulk measurements to characterize cytotoxicity at the single-cell level, serial killing capacity, and phenotypic profiles in a single run, providing unprecedented depth of insight into immune cell potency and behaviour.
Bring an entire analytical lab into a single box
VivaCyte® automates everything from sample preparation to AI image analysis, delivering high-throughput serial killing, cytotoxicity, and cytokine data at single-cell resolution.
APPLICATIONS
VivaCyte enables a diverse set of applications for cell therapy research and development
LATEST NEWS
Press release
Karolinska Institutet and Cellply announce collaboration to advance NK cell-based therapy translational research with the VivaCyte platform
9 May 2025
Webinar
Webinar: A new automated potency analysis technique for suspension cells
25 November 2024
Events
Cellply Named in Cohort 2 of EIC Scaling Club for EU Deep Tech Scale-ups
6 November 2024
Press release
Cellply Introduces Revolutionary High-Throughput Potency Analysis Technique at SITC 39th Annual Meeting
31 October 2024
Webinar
Webinar: Uncovering hidden immune cell killing to understand anti-tumor activity
2 October 2024
Webinar
Cellply is pleased to announce its participation in European Biotech Week 2024 hosting an open webinar exploring the unique assay flexibility of VivaCyte
9 September 2024
News
Eurofins Biopharma Product Testing (BPT) Italy and Cellply announce strategic partnership to foster cell and gene therapy development through single-cell characterisation
29 August 2024
Webinar
Webinar: Rapid single cell functional characterization for cell therapy potency
12 July 2024
News
Cellply passed the phase 2 of Call4Innovit program and will go to San Francisco
23 May 2024
Events
Advancing TCR-based Cell Therapies & Bispecific Approaches
24 April 2024
Press release
Nature Biotechnology publishes research from DKFZ and Cellply highlighting novel approach for accelerating cellular immunotherapy development
19 March 2024
Events
Dual attendance for Cellply at March’s leading events in the cell therapy industry.
18 March 2024
Events
Launch of VivaCyte® at Advanced Therapies Week 2024
26 January 2024
News
Cellply launches its end-to-end single cell potency characterization platform VivaCyte
17 January 2024
Events
Cellply at Advanced Therapies Week 2024
4 January 2024
News
Cellply – Fesr programme 2021-2027
28 December 2023
Press release
Cellply concludes a new internal round of €3.6 million and extends the round to new investors!
27 September 2023
News
CellPly announces acceptance of one abstract at the CICON23 conference
18 September 2023
Press release
CellPly announces Emiliano Spagnolo as the new CEO
27 July 2023
News
L’innovazione Cellply in un articolo sulla rivista Le Scienze
4 March 2020
Events
Cellply to present new method for evaluating immunotherapy efficacy at the 61th ASH Annual Meeting
25 November 2019
News
Cellply wins the €300k Gaetano Marzotto prize and Unicredit StartLab prize
22 November 2018
Events
Cellply invited to present at the World Health Summit 2019
22 October 2018
News
Cellply selected as finalist at Lyfebulb Oncology Award
1 March 2018
Events
Cellply abstract accepted at the AACR 2018 Annual Meeting
4 February 2018
Press release
Cellply and Sant’Orsola-Malpighi Polyclinic to present one abstract on AML patient stratification with the Open Microwell platform at the 58th ASH Annual Meeting
4 November 2016
News
Cellply wins an H2020 SME Instrument Phase 1 grant
20 October 2016